Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Expands By 5.1%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 684,800 shares, an increase of 5.1% from the May 15th total of 651,500 shares. Based on an average daily volume of 91,700 shares, the days-to-cover ratio is presently 7.5 days. Approximately 6.3% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on JSPR shares. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Wednesday, May 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research note on Tuesday. Royal Bank of Canada started coverage on Jasper Therapeutics in a research note on Thursday, March 28th. They set an “outperform” rating and a $70.00 target price for the company. TD Cowen started coverage on Jasper Therapeutics in a research note on Monday, March 18th. They set an “outperform” rating for the company. Finally, Oppenheimer reissued an “outperform” rating and set a $80.00 target price on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics presently has an average rating of “Buy” and an average price target of $64.29.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of JSPR. Opaleye Management Inc. purchased a new stake in Jasper Therapeutics in the 4th quarter valued at $3,144,000. Kingdon Capital Management L.L.C. increased its position in shares of Jasper Therapeutics by 16.4% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after purchasing an additional 500,000 shares during the last quarter. Fernwood Investment Management LLC increased its position in shares of Jasper Therapeutics by 8.8% during the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock valued at $390,000 after purchasing an additional 40,000 shares during the last quarter. Monaco Asset Management SAM purchased a new stake in shares of Jasper Therapeutics during the 4th quarter valued at $197,000. Finally, StemPoint Capital LP purchased a new stake in shares of Jasper Therapeutics during the 1st quarter valued at $3,794,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $23.19 on Thursday. The business’s 50 day simple moving average is $23.57 and its 200 day simple moving average is $18.62. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01. The stock has a market capitalization of $349.33 million, a PE ratio of -4.12 and a beta of 2.24.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.23. As a group, research analysts expect that Jasper Therapeutics will post -4.36 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.